Table 3

Efficacy and safety endpoints (N=76)

Half-dose rt-PA
n=38 (%)
LMWH
n=38 (%)
P value
Primary composite outcomes within 30 days
 Mortality in the first 7 days1 (3)2 (5)1.000
 Mortality from 7 to 30 days0 (0)2 (5)0.493
 Total mortality in the first 30 days1 (3)4 (10)0.358
 Death/hemodynamic decompensation in the first 7 days1 (3)8 (21)0.028
 Death/hemodynamic decompensation in the first 30 days1 (3)10 (26)0.009
Secondary endpoints (6 months after starting treatment)
 Persistence of pulmonary artery filling defect on CTPA7 (20)6 (19)1.000
 Mean PASP on echocardiography33±1433±190.504
 Pulmonary hypertension (≥40 mm Hg on echocardiography)9 (24)7 (18)0.778
 Recurrent embolism2 (5)1 (3)1.000
Safety outcome (bleeding)
 Minor bleeding8 (21)4 (10)0.223
 Major bleeding3 (8)2 (5)1.000
 Age >75 (n=25)1 (7)2 (18)0.4
 Age <75 (n=51)2 (8)0
  • CTPA, CT pulmonary angiography; LMWH, low molecular weight heparin; PASP, pulmonary artery systolic pressure >40 mm Hg; rt-PA, tissue-type plasminogen activator.